RxDoctor Payments Data

Traci Schumacher

Psychiatric/Mental Health · Erie, PANPI 1700517901

Payments from drug & device makers

$2,677in general payments, 2019–2025

Across 160 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$912
  • Otsuka America Pharmaceutical, Inc.$355
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$275
  • E.r. Squibb & Sons, L.L.C.$235
  • Alkermes, Inc.$201
  • Vanda Pharmaceuticals Inc.$193
  • plus $507 from 7 others

What the payments were for

  • Food & beverage$2,56696%
  • Education$1114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,677 in reported general payments places this provider in the 80th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,101
Medicare patients
11
Services billed
15

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VivitrolNaltrexone Microspheres13$21,869
Buspirone Hcl30$607
Naltrexone Hcl11$333
Duloxetine Hcl22$302
Hydroxyzine Pamoate22$301
Olanzapine20$295
Quetiapine Fumarate24$279
Trazodone Hcl20$214
Bupropion XlBupropion Hcl19$211
Gabapentin18$206
Mirtazapine16$126
Venlafaxine Hcl ErVenlafaxine Hcl14$125
Sertraline Hcl12$115
Lithium Carbonate16$96
Escitalopram Oxalate12$89

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Vivitrol$201$21,86913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →